Yin, C.; Ethier, J.-L.; Carey, M.S.; Tu, D.; Zheng, X.
Trajectories of Cancer Antigen 125 (CA125) Within 3 and 6 Months After the Initiation of Chemotherapy Treatment for Advanced Ovarian Cancer and Clinical Outcomes: A Secondary Analysis of Data from a Phase III Clinical Trial. Curr. Oncol. 2025, 32, 390.
https://doi.org/10.3390/curroncol32070390
AMA Style
Yin C, Ethier J-L, Carey MS, Tu D, Zheng X.
Trajectories of Cancer Antigen 125 (CA125) Within 3 and 6 Months After the Initiation of Chemotherapy Treatment for Advanced Ovarian Cancer and Clinical Outcomes: A Secondary Analysis of Data from a Phase III Clinical Trial. Current Oncology. 2025; 32(7):390.
https://doi.org/10.3390/curroncol32070390
Chicago/Turabian Style
Yin, Chang, Josee-Lyne Ethier, Mark S. Carey, Dongsheng Tu, and Xueying Zheng.
2025. "Trajectories of Cancer Antigen 125 (CA125) Within 3 and 6 Months After the Initiation of Chemotherapy Treatment for Advanced Ovarian Cancer and Clinical Outcomes: A Secondary Analysis of Data from a Phase III Clinical Trial" Current Oncology 32, no. 7: 390.
https://doi.org/10.3390/curroncol32070390
APA Style
Yin, C., Ethier, J.-L., Carey, M. S., Tu, D., & Zheng, X.
(2025). Trajectories of Cancer Antigen 125 (CA125) Within 3 and 6 Months After the Initiation of Chemotherapy Treatment for Advanced Ovarian Cancer and Clinical Outcomes: A Secondary Analysis of Data from a Phase III Clinical Trial. Current Oncology, 32(7), 390.
https://doi.org/10.3390/curroncol32070390